DaVita Inc. DVA SPX

Healthcare · Medical Care Facilities · United States

https://www.davita.com

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Market & Price

Market Cap

$12.47B

Current Price

$194.36

High / Low (52W)

$200.54 / $103.87

Beta

0.84

Valuation

Stock P/E

18.72

Industry PE

23.65

Forward P/E

11.31

PEG Ratio

0.60

Book Value

$-11.41

Price to Book

-17.03

P/S

0.90

EV/EBITDA

9.61

Dividend Yield

Profitability & Returns

ROCE

13.44%

ROE

80.98%

ROA

7.50%

Profit Margin

5.65%

Op Margin

13.86%

EPS (Latest Qtr)

$2.87

EPS (TTM)

$10.38

Balance Sheet & Liquidity

Debt/Equity

12.61

Quick Ratio

1.28

Current Ratio

1.42

Debt

$13.22B

Total Assets

$17.48B

Current Assets

$4.06B

Working Capital

$916.37M

Ownership

Promoter Holding

50.55%

Chg in Prom Hold

-0.01%

FII / Inst Holding

52.05%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$26.84B

Total Revenue (TTM)

$13.84B

EBITDA

$2.79B

Free Cash Flow

$999.66M

Operating Cash Flow

$2.03B

Shares Outstanding

64.19M

Gross Margin

32.45%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

5.53%

Profit 5Y

10.04%

Revenue (YoY)

6.00%

Earnings (YoY)

43.50%

PROS

Strong return on equity of 81.0%.
Profit CAGR of 10.0% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	DVA DaVita Inc. SPX	194.36	18.72	$12.47B	-	13.44%	80.98%	5.53%	10.04%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	2.63B	2.70B	2.77B	2.78B	2.85B	2.89B	2.85B	2.82B	2.74B	2.84B	2.90B	2.90B	2.84B	2.88B	2.92B	2.91B	2.82B	2.92B	2.94B	2.82B	2.93B	2.95B	2.87B	3.00B	3.12B	3.07B	3.19B	-	-	3.22B	3.38B	3.42B	3.62B	3.42B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.24B	2.26B	2.33B	2.41B	2.34B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	983.87M	1.12B	1.09B	1.21B	1.07B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	550.54M	587.51M	591.86M	659.07M	599.74M
Operating Income	509.37M	244.94M	422.03M	431.13M	813.10M	363.44M	875.93M	391.20M	395.29M	150.34M	410.69M	438.19M	289.04M	387.91M	340.51M	461.89M	378.34M	462.59M	465.38M	409.92M	437.67M	381.67M	442.60M	490.48M	474.88M	338.31M	432.71M	311.79M	311.64M	405.29M	495.94M	483.85M	506.40M	-	-	433.33M	530.48M	495.61M	551.21M	473.55M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	597.84M	689.69M	636.85M	717.71M	664.19M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	135.06M	146.06M	150.56M	148.25M	145.13M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	286.33M	368.93M	308.80M	382.76M	341.23M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	54.12M	93.71M	68.55M	76.73M	66.20M
Net Income	215.87M	-6.00M	97.43M	53.38M	571.33M	157.73M	447.70M	127.00M	-214.48M	303.40M	178.69M	267.28M	-136.80M	-149.77M	149.29M	273.55M	143.27M	244.87M	239.59M	201.60M	158.67M	173.77M	237.40M	293.82M	259.75M	162.12M	224.81M	105.37M	115.55M	178.69M	246.63M	239.65M	222.68M	-	-	162.92M	199.34M	150.33M	234.22M	197.53M
Diluted EPS	1.00	-0.03	0.47	0.26	2.76	0.80	2.29	0.65	-1.12	1.64	0.98	1.53	-0.82	-0.90	0.90	1.64	0.95	1.88	1.89	1.62	1.28	1.50	2.09	2.64	2.36	1.61	2.30	1.13	1.25	1.91	2.62	2.65	2.50	-	-	2.00	2.58	2.04	3.29	2.87

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	10.71B	10.88B	11.40B	11.39B	11.55B	-	11.61B	12.14B	12.82B	13.64B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.21B	8.32B	8.60B	9.24B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.40B	3.82B	4.22B	4.40B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.09B	2.22B	2.26B	2.39B
Operating Income	908.91M	869.10M	939.63M	993.81M	1.15B	1.30B	1.55B	1.82B	1.14B	2.03B	1.81B	1.53B	1.64B	1.69B	-	1.31B	1.60B	1.95B	2.01B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.06B	2.32B	2.72B	2.64B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	357.02M	398.55M	470.47M	579.93M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	966.28M	1.18B	1.53B	1.35B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	198.09M	220.12M	279.66M	293.11M
Net Income	381.78M	374.16M	422.68M	405.68M	478.00M	536.02M	633.45M	723.11M	269.73M	879.87M	663.62M	159.39M	810.98M	773.64M	-	560.40M	691.53M	936.34M	746.80M
Diluted EPS	3.55	3.53	4.06	3.94	2.48	2.74	2.95	3.33	1.25	4.29	3.47	0.92	5.27	6.31	-	5.85	7.42	10.73	9.84

Compounded Sales Growth

5 Years:	5.53%
1 Year:	6.00%

Compounded Profit Growth

5 Years:	10.04%
1 Year:	43.50%

Stock Price Performance

1 Year:	+42.64%
6 Months:	+60.14%
3 Months:	+24.35%
1 Month:	+27.88%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	7.29B	7.56B	8.11B	8.90B	16.01B	17.10B	17.62B	18.51B	18.76B	18.97B	19.11B	17.31B	16.99B	-	16.93B	16.89B	17.29B	17.48B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.16B	3.14B	3.75B	4.06B
Cash & Equivalents	310.20M	447.05M	410.88M	539.46M	860.12M	393.75M	533.75M	946.25M	736.90M	1.24B	674.78M	508.23M	323.04M	1.10B	324.96M	-	244.09M	380.06M	794.93M	676.44M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	109.12M	143.10M	134.56M	160.63M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.13B	1.99B	2.15B	2.41B
Total Liabilities	-	-	5.17B	5.03B	5.69B	6.16B	11.52B	11.80B	11.43B	12.57B	12.93B	13.08B	14.08B	13.81B	14.09B	-	14.70B	14.15B	15.19B	16.32B
Current Liabilities	-	-	1.16B	1.05B	924.35M	1.16B	2.02B	2.46B	2.09B	2.40B	2.71B	3.07B	4.89B	2.37B	2.48B	-	2.62B	2.64B	2.97B	3.14B
Long Term Debt	-	-	3.62B	3.53B	4.23B	4.42B	-	-	-	-	-	-	-	-	-	-	8.69B	8.27B	9.18B	10.16B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.82B	11.12B	12.07B	12.87B
Total Equity	-	-	1.77B	2.14B	1.98B	2.14B	3.76B	4.43B	5.17B	4.87B	4.65B	4.69B	3.70B	2.13B	1.38B	-	712.33M	1.06B	121.12M	-651.08M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	90.41M	88.82M	90.37M	68.55M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	581.07M	613.70M	666.71M	839.68M	1.18B	1.10B	1.77B	1.46B	1.56B	1.97B	1.91B	1.77B	2.07B	1.98B	-	1.56B	2.06B	2.02B	1.89B
Investing Cash Flow	-446.74M	-397.74M	-346.06M	-436.63M	-1.40B	-4.83B	-876.88M	-1.28B	-881.78M	-1.20B	-1.36B	-1.01B	3.00B	-825.37M	-	-630.35M	-771.80M	-771.43M	-654.95M
Financing Cash Flow	2.52M	-252.13M	-192.07M	-82.39M	-247.18M	3.87B	-482.99M	-164.98M	-138.97M	-1.35B	-766.26M	-625.35M	-4.70B	-1.85B	-	-1.12B	-1.17B	-816.94M	-1.37B
Capital Expenditure	-272.21M	-317.96M	-274.61M	-273.60M	-400.16M	-550.15M	-617.60M	-641.33M	-708.00M	-829.10M	-905.25M	-987.14M	-766.55M	-674.54M	-	-603.43M	-567.99M	-555.44M	-575.86M
Free Cash Flow	308.85M	295.74M	392.11M	566.08M	779.89M	550.70M	1.16B	818.08M	849.20M	1.14B	1.01B	784.50M	1.31B	1.30B	-	961.14M	1.49B	1.47B	1.31B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-186.91M	116.74M	433.67M	-143.23M
Share Buybacks	6.35M	232.72M	153.50M	618.50M	323.35M	-	-	-	549.93M	1.10B	802.95M	1.16B	2.38B	1.46B	1.54B	802.23M	272.22M	1.39B	1.31B

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	29.3%	31.5%	32.9%	32.2%
Operating Margin %	-	-	-	-	-	-	-	-	-	19.0%	16.7%	13.4%	14.4%	14.7%	-	11.3%	13.2%	15.3%	14.7%
Net Margin %	-	-	-	-	-	-	-	-	-	8.2%	6.1%	1.4%	7.1%	6.7%	-	4.8%	5.7%	7.3%	5.5%
ROE %	-	21.2%	19.8%	20.5%	22.3%	14.2%	14.3%	14.0%	5.5%	18.9%	14.1%	4.3%	38.0%	55.9%	-	78.7%	65.5%	773.1%	-114.7%
ROCE %	-	14.2%	14.4%	13.8%	14.9%	9.3%	10.6%	11.7%	7.1%	12.7%	11.4%	10.7%	11.0%	11.7%	-	9.2%	11.2%	13.7%	14.0%

Shareholding Pattern

Insiders

50.55%

Institutions

52.05%

Public Float

105.25%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Berkshire Hathaway, Inc	46.89%	30.10M	$5.85B
2	Blackrock Inc.	4.31%	2.77M	$537.75M
3	Vanguard Capital Management LLC	3.40%	2.18M	$423.75M
4	Morgan Stanley	2.60%	1.67M	$323.81M
5	Vanguard Portfolio Management LLC	2.30%	1.48M	$287.58M
6	Invesco Ltd.	2.29%	1.47M	$285.30M
7	State Street Corporation	2.11%	1.35M	$262.72M
8	Dimensional Fund Advisors LP	1.78%	1.15M	$222.63M
9	Arrowstreet Capital, Limited Partnership	1.73%	1.11M	$215.77M
10	Geode Capital Management, LLC	1.46%	939.78K	$182.66M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for DVA

No recent headlines available.

DVA · Healthcare

DaVita Inc.

About

Key Facts

Sector	Healthcare
Industry	Medical Care Facilities
Headquarters	United States
Employees	78,000
Website	https://www.davita.com

Press Esc or click outside to close.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

DaVita Inc. DVA SPX

Market & Price

Valuation

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Growth (CAGR)

PROS

CONS

Price Chart

Technical Trend

Fundamental Growth

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Explore More